Moreover, differences between the US and Norway, such as higher prostate cancer incidence and mortality rates in Norway [6,26], as well as historically a higher prevalence of PSA testing in the US [27,28], underscore the need for context-specific analysis. The gene discussed is KLK3; the disease is prostate carcinoma.